

eISBN: 978-1-68108-347-6
ISBN: 978-1-68108-348-3

CANCER METASTASIS AND CANCER STEM CELL/NICHE

Editor:
Takanori Kawaguchi

Bentham e Books

Cancer Metastasis and Cancer Stem Cell/Niche

Edited by:

Takanori Kawaguchi

Division of Human Life Sciences

Fukushima Medical University School of Nursing

Fukushima

Japan

&

Department of Pathology

General Aizu Chuo Hospital

Fukushima

Japan

Cancer Metastasis and Cancer Stem Cell/Niche

Editor: Takanori Kawaguchi

ISBN (eBook): 978-1-68108-347-6

ISBN (Print): 978-1-68108-348-3

©2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2016.

Acknowledgements

I make a grateful acknowledgement for Mrs. Michiko Hoshi, who works in preparation of this book.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2
PO Box 7917, Saif Zone
Sharjah, U.A.E.
Email: subscriptions@benthamscience.org



CONTENTS

FOREWORD	i
PREFACE	iii
BIOGRAPHY	iv
LIST OF CONTRIBUTORS	v
CHAPTER 1 FUNDAMENTAL RELATIONSHIPS BETWEEN CANCER STEM CELLS, THE CANCER STEM CELL NICHE AND METASTASIS	3
<i>Gt le'FOl qwpi . 'Nkpj gpi 'Nk'Hctkdc'Dgi daf 'and'Fcpp{ 'TOY grej</i>	
INTRODUCTION	4
FEATURES OF STEMNESS	4
Stem Cells in Normal Physiology and Development	4
The Cancer Stem Cell Phenotype	5
<i>Morphology, Differentiation and Self Renewal</i>	5
<i>Mitotic Activity</i>	7
<i>Protein and Biomarker Expression</i>	8
<i>Metabolism</i>	9
Metastasis Initiating Cells	10
<i>Critical Components of Metastasis</i>	10
<i>Epithelial-to-Mesenchymal Transition</i>	11
<i>Mechanisms of Metastasis</i>	12
Contributions of the Niche	13
<i>The Normal Stem Cell Niche</i>	13
<i>The CSC Niche</i>	14
<i>The Metastatic Niche</i>	14
CONCLUSION	15
CONFLICT OF INTEREST	16
ACKNOWLEDGEMENTS	17
REFERENCES	17
CHAPTER 2 REGULATION OF CELL SURFACE GLYCAN EXPRESSION IN CANCER STEM CELLS	24
<i>TghkMcppci k'Dk'J g'Eck'J ukcpi /Ej k'J wpi 'and'Mgkcej ktq'Ukmo c</i>	
INTRODUCTION	25
CANCER STEM CELLS AND EPIGENETIC SILENCING OF GLYCOGENES	25
Induction of Typical Cancer-associated Glycans Through Epigenetic Silencing of Glycan-related Genes Responsible for Synthesis of Normal Glycans	25
Mechanisms for Epigenetic Silencing of Glycan-related Genes During the Course of Carcinogenesis	28
Differentiation-dependent Expression of Glycans in Normal Tissue Stem Cells	31
ENHANCED STEMNESS AND ALTERED GLYCAN EXPRESSION BY TUMOR HYPOXIA	34
Acquisition of Resistance to Hypoxia by Cancer Cells in Advanced Stage of Cancers	34
Normal Stem Cells and Their Hypoxic Niches	35
STEM CELLS AND GLYCAN ALTERATION IN EPITHELIO-MESENCHYMAL TRANSITION	38
Glycan Alteration in Epithelio-mesenchymal Transition of Cancer Cells	38

Normal Stem Cells and Plasticity to Undergo EMT/MET	41
GLYCANS ASSOCIATED WITH HUMAN EMBRYONIC STEM CELLS AND CANCER STEM CELLS	42
Appearance of Classical Human Embryonic Stem Cell Marker Glycans, SSEA-3/-4, in Cancer Stem Cells	42
Lactoseries Glycans Recently Emerging as Human Embryonic and Cancer Stem Cell Markers	46
CONCLUSION	48
CONFLICT OF INTEREST	49
ACKNOWLEDGEMENTS	49
REFERENCES	49
CHAPTER 3 TUMOR ENDOTHELIAL CELLS AND CANCER PROGRESSION	61
<i>Ml qnu'J kfc. 'Pcmq'Ockj k'Fqtecu'COcpcp'and'J cwsj kq'J kfc</i>	
TUMOR ANGIOGENESIS	62
TUMOR BLOOD VESSELS ARE MORPHOLOGICALLY ABNORMAL	62
DIFFERENCES BETWEEN TUMOR ENDOTHELIAL CELLS AND NORMAL ENDOTHELIAL CELLS	64
HETEROGENEITY OF NORMAL ENDOTHELIAL CELLS	65
TEC HETEROGENEITY	65
DRUG RESISTANCE AND CYTOGENETIC ABNORMALITIES IN HM-TECS	66
MECHANISMS OF TEC HETEROGENEITY	67
CONCLUSION	68
FUNDING	68
DISCLOSURE	68
CONFLICT OF INTEREST	69
ACKNOWLEDGEMENTS	69
REFERENCES	69
CHAPTER 4 METASTATIC CANCER STEM CELL NICHE AND THE TOLL-LIKE RECEPTOR 4 (TLR4)-MEDIATED PREMETASTATIC MICROENVIRONMENT	74
<i>Vcnguj kVqo kc. 'Cunwuy'F gi wej k'and'J quj kq'Octw</i>	
I. OVERVIEW	74
I-a. Outline of Tumor Metastasis	74
I-b. Traffic Accident Theory	77
I-c. Organ Tropism of Tumor Metastasis	78
I-d. Pre-metastatic Phase	79
II. CANCER STEM CELL, RECENT PROGRESS	80
II-a. Definition of Cancer Stem Cell	80
II-b. Metastatic Stem Cell	81
II-c. Cancer Stem Cell and Markers	81
II-d. Cancer Stem Cells and EMT (Epithelial-mesenchymal Transition)	82
II-e. Tumor Heterogeneity	83
III. CANCER STEM CELL MODELS	84
III-a. Clonal Evolution Model	84
III-b. Classical Cancer Stem Cell Model	84
III-c. Plastic Cancer Stem Cell Model	84
III-d. Cancer Stem Cells From Non-cancer Stem Cells	84
IV. CANCER STEM CELL AND PRE-METASTATIC NICHE	85
V. TUMOR MICROENVIRONMENT AND CANCER STEM CELL NICHE	90
VI. INTERACTION BETWEEN TUMOR CELLS AND STROMAL CELLS	91
VI-a. Tumor-associated Monocytes/macrophages	92
VI-b. Tumor-associated Fibroblasts	92
VI-c. Tumor-associated Adipocytes	93

VI-d. Tumor-associated Dendritic Cells	93
VI-e. Tumor-associated Neutrophils	94
VI-f. Tumor-associated Natural Killer Cells	94
VII. DORMANT TUMOR CELLS	94
VIII. CIRCULATING TUMOR CELLS	96
IX. RESHAPING PRE-METASTATIC NICHE MODELS	98
X. CONCLUSION	99
CONFLICT OF INTEREST	99
ACKNOWLEDGEMENTS	99
REFERENCES	100

CHAPTER 5 CANCER STEM CELL AND CLINICAL CANCER METASTASIS IN SURGICAL ONCOLOGY 109

Uj qll'Pcno qt k'and'Mqll'O qt ko qvq

INTRODUCTION	110
CLINICAL SIGNIFICANCE OF METASTASIS IN SURGERY	111
BIOMARKERS OF CSC	113
CSC AND PROGNOSIS	115
CSC AND THERAPEUTIC APPLICATION IN SURGERY	117
CONCLUSION	120
CONFLICT OF INTEREST	120
ACKNOWLEDGEMENTS	120
REFERENCES	121

SUBJECT INDEX 134

FOREWORD

Our knowledge of cancer progression has grown exponentially since the discovery of oncogenes and our ability to model carcinogenesis and cancer initiation. Still the major challenge faced by physicians is the prevention and treatment of metastasis, the main reason for cancer related deaths. Our understanding of metastasis has lagged behind that of primary tumor biology and even with a surge in metastasis research we are far behind grasping its complexities.

Progress has been hampered by the research paradigm itself, which states that metastasis is an extremely late event in micro-evolutionary and temporal scales and driven by a tumor centric view. This information was mostly derived from models that use highly genetically aberrant and aggressive cancer cell line models and ignored the tumor microenvironment in the target organs. Thus, the field has accepted that metastases are an aggressive variant of the primary tumor and that these lesions share most characteristics that are mostly autonomous. This conclusion supported that primary tumor information should be sufficient to target the metastasis. So far this paradigm has shown moderate success at best in revealing the intricacies of metastasis and very little in yielding successful therapies to stop metastasis.

This book on metastasis is timely as we are at a turning point in metastasis research, which will impact the future of patient's treatment. The focus of this book is key to highlight how little we understand about cancer metastasis but also shows how great progress has been made in understanding the complexities of metastasis. This includes accepting that the complexities of metastasis biology are different from the primary tumor and that the target organ microenvironments play key roles in defining the biology of the metastatic cancer cells.

The chapters in this book are centered around the idea that there are minor populations in primary tumors termed cancer stem cells or cancer initiating cells that appear to also have the power to fuel metastasis. The chapters cover the role of the microenvironment composed by stromal cells and immune cells in determining the fate of the primary tumor and metastasis progression. The role of pre-metastatic microenvironments is also highlighted and the cancer stem cell concept is integrated with how niche signals impact epigenetic mechanisms that affect the expression of surface markers such as glycans to regulate the CSC behavior. The authors also cover the areas of secreted vesicles as important signaling mediators between the tumor and the stroma and the role of angiogenesis, which is a clear factor for metastatic maintenances. One chapter is focused on the development of imaging modalities to improve the detection of rare cell subpopulations in tumor lesions, and such advancements are critically needed. This becomes critical when thinking that after surgery and treatment and before metastatic outgrowth there is a period of minimal residual disease (MRD). This periods

can last for decades when the seeds of metastasis are dormant and for which we have no evidence-based treatment and imaging modalities. Unfortunately this stems primarily from the lack of our understanding of the biology that defines MRD, dormancy and reactivation. However, the chapters will illustrate that the field has moved forward significantly and new findings are routinely published that are expanding our understanding of metastasis and how to target it.

As mentioned before this book comes at a time when a change is needed if we are going to be successful in targeting metastasis and that requires deepening our understanding of the biology of disseminated disease, developing markers to detect it, image it and come up with new therapeutic strategies that are based on the direct knowledge of MRD biology and metastasis and not inferred from extrapolations based on primary tumor information, that is sometimes gathered a decade or more before manifestation of the metastasis and thus may be a very different disease. The work highlighted in this book is a testament of the excellent work being developed worldwide to target this deadly step of the disease and possibly our best short-term chance to change the course of cancer treatment and improve patient's life.

Julio Aguirre-Ghiso

Division of Hematology and Oncology

Department of Medicine

Department of Otolaryngology

Department of Oncological Sciences

Tisch Cancer Institute at Mount Sinai

Ichan School of Medicine at Mount Sinai

New York, USA

PREFACE

A malignant tumor is an actively growing tissue, composed of cells derived from a single cell that has undergone abnormal irreversible differentiation. These cells have two fundamental qualities: invasion and metastasis that induce the risk of cancer. Interestingly, recent researchers suggest that a malignant tumor is originated from cancer stem cells (CSC) accompanied with the niches. In this eBook, I would like to ask how the invasion and metastasis of cancer cells are explained by CSC theory and/or niche theory. The major points are as follows.

1. The fundamental aspects of cancer:
 1. The first point of discussion is about the CSC/ niche in carcinoma *in situ* lesion which appears in various types of cancer including breast and bladder cancers. Where is the niche corresponding to CSC in the above situation and what is the role of the niche in cancer progression?
 2. Cancer metastasis involves two characteristic occurrences: “organ preference metastasis” and “metastatic potential”. Can these metastatic characteristics be explained by CSC /niche theory well?
2. Metastatic phenotypes:

The mechanisms of cancer metastasis include non-invasiveness (carcinoma *in situ*), lateral/side invasion, stromal invasion, intravasation, circulation, arrest, attachment, extravasation, early growth, growth, and sometimes secondary/tertiary metastasis. This is followed by cellular/molecular mechanisms including cellular adhesion molecules such as carbohydrates, chemotactic activity by producing pseudopodia and invadopodia, deformability/plasticity and cytostreaming of metastatic cancer cells, and survival of metastatic cancer cells in floating (substrate-independent condition). Can these phenotypes of metastatic cancer cells be explained by cancer stem cell theory?
3. The goal of this study is clinical application of the knowledge obtained by CSC/niche theory. CSC/niche targets have important therapeutic implications. The role of CSC/ niche on therapies for the prevention, maintenance therapy, personalized care, and perhaps even integrative care of cancer will be discussed.

Takanori Kawaguchi

Division of Human Life Sciences


Fukushima Medical University School of Nursing, Fukushima, Japan

Department of Pathology

General Aizu Chuo Hospital, Fukushima, Japan

Biography

My research on cancer metastasis began in 1968, at the 2nd Department of Pathology, Fukushima Medical University College of Medicine (Professor and Chairman, Kyuya Nakamura) and continued till 2006. Since 2006, I have been working at the Division of Nursing (Professor and Chairman, Takashi Honda) and the Department of Pathology, Aizu Chuo Hospital (Head, Takanori Kawaguchi). During this period, I collaborated with many researchers. In 1980, I visited the Department of Tumor Biology, MD Anderson Cancer Center and Tumor Institute in Houston (Professor and Chairman, Garth L. Nicolson), where I studied the metastasis of B16 melanoma variant sublines for a year. During the past 50 years, there have been great advances in metastasis research, for example, electron microscopy revealed cellular/subcellular behavior of tumor cells in metastasis. Molecular biology facilitated identification of the molecules involved in metastasis. For the last 100 years, the biggest issue associated with cancer metastasis research was a conflict of “anatomical-mechanical theory” and “seed and soil theory.” However, our research indicated that the anatomical–mechanical theory can be replaced by tissue injury hypothesis (microinjury hypothesis), and this concept was supported by the large scale of research on human cancer. Thus, I believe that metastasis occurs in the affinity of tumor cells and soil (niche), where soil causes the tumor cells to become immature.



Takanori Kawaguchi

List of Contributors

- Atsuko Deguchi** Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan
- Bi-He Cai** The Institute of Biomedical Sciences (IBMS), Academia Sinica, Taipei, Taiwan
Department of Cancer Biology, The University of Kansas Medical Center, Kansas, USA
- Danny R. Welch** Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas, USA
The University of Kansas Cancer Center, Kansas, USA
- Dorcas A. Annan** Vascular Biology, Frontier Research Unit, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
- Eric D. Young** Department of Cancer Biology, The University of Kansas Medical Center, Kansas, USA
Department of Cancer Biology, The University of Kansas Medical Center, Kansas, USA
- Fariba Behbod** Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas, USA
The University of Kansas Cancer Center, Kansas, USA
- Hsiang-Chi Huang** The Institute of Biomedical Sciences (IBMS), Academia Sinica, Taipei, Taiwan
- Keiichiro Sakuma** Division of Molecular Pathology, Aichi Cancer Center, Nagoya, Japan
Department of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital, Osaka, Japan
Osaka Women's Junior College, Osaka, Japan
- Koji Morimoto**
- Kyoko Hida** Vascular Biology, Frontier Research Unit, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
- Linheng Li** Department of Cancer Biology, The University of Kansas Medical Center, Kansas, USA
Stowers Institute for Medical Research (SIMR), Missouri, USA
The University of Kansas Cancer Center, Kansas, USA
- Nako Maishi** Vascular Biology, Frontier Research Unit, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
- Reiji Kannagi** The Institute of Biomedical Sciences (IBMS), Academia Sinica, Taipei, Taiwan
Advanced Medical Research Center, Aichi Medical University, Nagakute, Japan
- Shoji Nakamori** Department of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital, Osaka, Japan
- Takeshi Tomita** Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan

vi

Yasuhiro Hida Department of Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Yoshiro Maru Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan

Fundamental Relationships Between Cancer Stem Cells, the Cancer Stem Cell Niche and Metastasis

Eric D. Young¹, Linheng Li^{1,2,4}, Fariba Behbod^{1,3,4} and Danny R. Welch^{1,3,4,*}

¹ *Department of Cancer Biology, The University of Kansas Medical Center, Kansas, USA*

² *Stowers Institute for Medical Research (SIMR), Missouri, USA*

³ *Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas, USA*

⁴ *The University of Kansas Cancer Center, Kansas, USA*

Abstract: Parallels drawn between stem cells and cancer are not new. However, these shared features are becoming increasingly important as our understanding of disseminated, recurrent and metastatic cancer cell biology continues to develop. Indeed, nearly all cancer-related deaths are the result of recurrent and metastatic disease, highlighting the need for a more comprehensive schema of how tumors colonize new sites, resist therapy and evolve. In this chapter, we compare the phenotypes of stem cells, cancer stem cells (CSCs) and metastatic cells, highlighting notable points of contrast. We begin with an introduction to stem cell biology, tumor-initiating CSCs, metastatic cells and discuss shared features. The implication of the stem-like phenotype extends to many characteristics of cell biology: cell division, differentiation, morphology, gene expression, motility, invasion, clonogenicity, capacity for colonization, metabolism and the interaction of these cells with their surrounding microenvironment. Stem cell phenotypes are highly complex and, while there may be a number of shared features, there are important elements that are uniquely tissue-dependent. While staunch definitions based upon a single biomarker of stemness have proven inadequate in broader applications, seeing universal themes of the stem cell phenotype will provide critical insights for studying cancer. Our understanding of this complex biology is critical for developing rational and dynamic therapeutic interventions for patients with recurrent and metastatic cancer.

* **Corresponding author Danny R. Welch:** Department of Cancer Biology, The University of Kansas Medical Center, 3901 Rainbow Blvd., Wahl Hall West 2003, Mailstop 1071, Kansas City, Kansas, 66160, USA; Tel: +1-913-945-7739; Fax: +1-913-588-4701; Email: dwelch@kumc.edu.

Keywords: Biomarker, Cancer stem cell, Cancer stem cell niche, Clonogenicity, Dissemination, Dormancy, Epithelial-mesenchymal transition, Heterogeneity, Metabolism, Metastasis, Metastasis-initiating cells, Metastatic cell, Metastatic colonization, Metastatic niche, Pluripotency, Quiescence, Review, Self-renewal, Stem cell, Stem cell niche, Tumor progression, Tumorigenesis, Tumorigenic cells, Tumor-initiating cell.

INTRODUCTION

The observation that features of a cancer cell resemble developmentally primitive cells dates back over 150 years [1]. This has proven to be a perspicacious observation indeed, given the similarities between cancer cells and stem cells with respect to their dynamic regulation of mitosis, gene expression, migration, metabolism and self-sustainability. Cell division is a critical component of carcinogenesis and early observations prompted the notion that cancer may arise from a stem cell [2, 3]. Additionally, the therapeutic significance of cancer cells displaying a stem cell-like phenotype has been more recently appreciated after patients whose cancer was treated with chemotherapy and were without evidence of disease, experienced recurrence of disease months or years later. These observations suggested that there was perhaps a population of mitotically quiescent cancer cells unaffected by chemotherapy that survived, proliferated and gave rise to the recurrent tumor or metastatic disease [4]. Tumor-initiating cells are the proposed “cancer stem cells” (CSCs). Given the importance of these phenotypes in the control of cancer, here we compare the shared and distinct biological features of normal stem cells, CSCs and metastatic cancer cells and consider the therapeutic significance of these insights.

FEATURES OF STEMNESS

Stem Cells in Normal Physiology and Development

Stem cells are populations of cells with the capacity to divide symmetrically, where the resulting daughter cells retain an equal potential to produce cells of a given lineage, or asymmetrically, resulting in more differentiated daughter cells that are narrowed in the variety of cells in that lineage they can produce [5]. *In vivo*, it was thought that stem cells spend the majority of their cell cycle in

mitotic quiescence [6], and upon stimulation by tissue damage or exogenous factors they can be induced to divide. More recently, in addition to quiescent stem cells, it has been shown that a population of Lgr5⁺stem cells also undergo active proliferation [7]. Daughter cells resulting from asymmetric divisions may become the more actively proliferating yet shorter-lived transit-amplifying cells which serve to regenerate tissue when required [8]. When stem cells are cultured *in vitro* however, conventional passaging methods may select for rapidly proliferating cells [9], explaining in part the dissonance between these two phenotypes. Ultimately, the orchestrated proliferation and differentiation of normal stem cells serve to reconstitute tissue lost to damage, aging and use. In a similar way, tumor cells remaining after selection by chemotherapy would be the “stem cells” of that tumor. These CSCs could eventually be stimulated to divide, resulting in the maintenance of slow-cycling CSCs. Stochastic changes in other daughter cells would re-establish tumor heterogeneity and a population of rapidly dividing cancer cells responsible for recurrence of disease.

The Cancer Stem Cell Phenotype

Morphology, Differentiation and Self Renewal

Discussion of CSCs envelops many concepts related to the origin of malignant cells, how selective processes change the tumor cell population over time (*i.e.* tumor progression), the ability of cells to successfully colonize new sites (*i.e.* metastasis), and the features of therapy-resistant cancer cells in disease recurrence (summarized in Table 1 and Fig. 1). Although a so-called “tumor initiating cell” may very well fit many of the aforementioned criteria, this nomenclature describes many of the later aspects of CSC biology without reference necessarily to their origin, with which we begin our discussion. Morphologic observations of cancers and embryonic tissues gave rise to the first ideas connecting cancer with stem cells. The strikingly heterogeneous composition of teratomas, containing teeth, hair, and sundry embryonic tissues led to the hypothesis that these tumors may come from a stem cell [10]. Further studies extended this observation and demonstrated the stemness of teratoma cells by showing their potential to differentiate into a multitude of tissues [11]. Beyond potency, normal stem cells, tumorigenic cancer cells and metastatic cells must all have the capacity for

Regulation of Cell Surface Glycan Expression in Cancer Stem Cells

Reiji Kannagi^{1,2,*}, Bi-He Cai¹, Hsiang-Chi Huang¹ and Keiichiro Sakuma³

¹ The Institute of Biomedical Sciences (IBMS), Academia Sinica, Taipei, Taiwan

² Advanced Medical Research Center, Aichi Medical University, Nagakute, Aichi, Japan

³ Division of Molecular Pathology, Aichi Cancer Center, Nagoya, Aichi, Japan

Abstract: Cell surface glycans are recognized to be good markers for human pluripotent embryonic stem cells. Typical glycan markers for human embryonic stem cells include SSEA-3, SSEA-4, TRA-1-60 and SSEA-5. Some of these glycans are recently known to be frequently expressed in human cancers, especially in cancer stem cells. Cell surface glycans undergo drastic changes also during malignant transformation, and the glycans which preferentially appear in cancers are clinically utilized as diagnostic markers for human cancers. Such tumor marker glycans include sialyl Lewis A and sialyl Lewis X, expression of which we recently showed to be enhanced in cancer stem-like cells that had undergone epithelial-mesenchymal transition. Sialyl Lewis A was also shown to be expressed in human embryonic stem cells, and to behave as an embryonic stem cell specific marker. Thus, a glycan initially described as a cancer-associated glycan in the cancer research field is now known to be an embryonic stem cell marker, while glycans formerly regarded to be typical embryonic stem cell markers in the embryology field are now shown to be cancer stem cell markers. This suggests the presence of a common induction mechanism for these glycans shared by embryonic stem cells and cancer stem cells. However, the regulatory mechanisms for stem-cell specific glycan expression remain largely unknown. In this chapter we will introduce how glycan-related genes responsible for synthesis of the stem-cell specific glycans are regulated through specific epigenetic modification, by niche-associated microenvironmental factors such as hypoxia, and during a morphogenic process like epithelial-mesenchymal transition.

* **Corresponding author Reiji Kannagi:** The Institute of Biomedical Sciences (IBMS), Academia Sinica, 128 Sec. 2, Academia Rd. Nankang, Taipei, 11529, Taiwan, R.O.C.; Tel/Fax: +886-2-2652-3976; Email: rkannagi@ibms.sinica.edu.tw.

Takanori Kawaguchi (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

Keywords: Cancer stem cells, DNA methylation, Dupan-2, Embryonic stem (ES) cells, Epigenetic silencing, Epithelial-mesenchymal transition (EMT), Histone deacetylation, Histone methylation, Hypoxia inducible factor, Selectins, Sialyl Lewis A, Sialyl Lewis X, Siglecs, SLC26A2, SSEA-3, SSEA-4, SSEA-5, ST6GalNAc6, Sulfate transporter, TRA-1-60.

INTRODUCTION

Perhaps the most important premise assumed in the theory of cancer stem cells is that they are derived from normal stem cells in the given tissue where the process of carcinogenesis takes place. If this is true, the cancer cells may inherit remnants of epigenetic patterns of gene expression from the normal stem cells through the epigenetic memory, and may share with them the common microenvironments which are termed as niche *in toto*, and will actively undergo extensive morphologic changes such as EMT/MET required for “organogenesis,” which may be represented as “metastasis” in the case of cancer cells. Of course the behavior of cancer stem cells will not be exactly the same as normal stem cells, as the cancer stem cells will exhibit novel features that will be acquired through the reprogramming process during the course of carcinogenesis. It is conceivable that although cancer initiating cells originate from normal tissue stem cells in the given organs, there is still not solid evidence indicating that the origin of cancer initiating cells is strictly confined to normal stem cells in every tissue and organ. Therefore, the terms “tumor-initiating cell,” “tumor-propagating cells” or “cancer stem-like cell” are sometimes recommended instead of cancer stem cell. There is, however, no doubt that the concept of cancer stem cells has significantly contributed to our understanding of many biological aspects of cancers.

CANCER STEM CELLS AND EPIGENETIC SILENCING OF GLYCOGENES

Induction of Typical Cancer-associated Glycans Through Epigenetic Silencing of Glycan-related Genes Responsible for Synthesis of Normal Glycans

It has long been known that glycans undergo drastic changes upon carcinogenesis. The glycans preferentially appear in cancer cells, such as sialyl Lewis A and sialyl

Lewis X, are utilized in clinical diagnosis of cancers. We recently showed that expression of these cancer-associated glycans is induced in cancer cells at the early stages of carcinogenesis through epigenetic silencing of several glycan-related genes responsible for synthesis of normal glycans.




Fig. (1). Examples of interconversion of normal glycans into cancer-associated glycans. Panel **A**, transition of normal glycan, disialyl Lewis A, to cancer-associated glycan, sialyl Lewis A, upon malignant transformation. Panel **B**, conversion of normal glycan, sialyl 6-sulfo Lewis X to a cancer-associated glycan, sialyl Lewis X glycan upon malignant transformation. Typical distribution patterns shown were obtained by immunohistochemical staining using specific anti-glycan antibodies of consecutive sections prepared from colon cancer tissues. Ca, cancer cells; N, non-malignant epithelial cells. (Adapted from references [5 - 7]).

A variety of glycans are expressed in normal epithelial cells, expression of some of which is conventional in that they are also constitutively expressed in cancers. In contrast, some other normal glycans exhibit preferential expression in non-malignant epithelial cells, and tend to decrease or disappear and be replaced by cancer-associated glycans upon malignant transformation. Such normal glycans

Tumor Endothelial Cells and Cancer Progression

Kyoko Hida^{1,*}, Nako Maishi¹, Dorcas A. Annan¹ and Yasuhiro Hida²

¹ *Vascular Biology, Frontier Research Unit, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan*

² *Department of Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan*

Abstract: Tumor growth and metastasis are facilitated by the formation of new blood vessels, a process known as angiogenesis. The blood vessels formed around the tumor supply it with oxygen and nutrients, which together support its progression. Moreover, the newly formed blood vessels serve as channels through which tumor cells metastasize to distant organs. Tumor blood vessels, and especially the endothelial cells lining tumor blood vessels (tumor endothelial cells, TECs), have therefore gained interest as targets in cancer therapy. Although newly formed tumor blood vessels originate from pre-existing, normal vessels, they have a distinctively abnormal phenotype, including important morphological alterations. The balance between the angiogenic stimulators and inhibitors regulates angiogenesis in the tumor microenvironment. Furthermore, TECs constitute a heterogeneous population, exhibiting characteristics induced largely by tumor microenvironmental factors. In this chapter we review recent studies on TEC abnormalities regarding to cancer progression and consider the therapeutic implications thereof.

Keywords: Angiogenesis, Angiogenic factor, Anti-angiogenic therapy, Basement membrane, Blood vessel, Cancer, Drug resistance, Endothelial cell, Heterogeneity, Hypoxia, Invasion, Metastasis, Migration, Pericyte, Side effect, Tumor, Tumor angiogenesis, VEGF.

* **Corresponding author Kyoko Hida:** Vascular Biology, Frontier Research Unit, Institute for Genetic Medicine, Hokkaido University, N15, W7, Kita-ku, Sapporo, 060-0815, Japan; Tel: +81-11-706-4315; Fax: +81-11-706-4325; E-mail: khida@igm.hokudai.ac.jp.

TUMOR ANGIOGENESIS

Angiogenesis leads to the formation of new blood vessels and is essential for tumor progression. Tumor blood vessels supply the tumor with needed oxygen and nutrients, in addition to removing waste products from tumor tissue. However, tumor vessels also provide a route to metastasis [1, 2]. The endothelial cells that line tumor blood vessels (TECs) have emerged as important targets of angiogenic inhibitors (anti-angiogenic therapy) and provide a strategy for cancer treatment, with many anti-angiogenic drugs developed and tested to date [3]. The basis for pursuing this therapy can be summarized as follows: i) The survival of a large population of tumor cells depends on a few TECs, such that targeting TECs may be more efficient than targeting tumor cells. ii) Since TECs exhibit similar characteristics regardless of their tumor of origin, a single, effective anti-angiogenic drug could be used to treat many forms of cancer. iii) It was thought that TECs are genetically stable unlike tumor cells, and therefore do not become drug resistant. However, recent studies have shown that TECs from primary tumor sites differ from normal endothelial cells (NECs) and their makeup in various tumor types is heterogeneous. Moreover, while anti-angiogenic drugs were thought to be less toxic than other cytotoxic drugs, it is now clear that they may induce severe side effects, such as lethal hemoptysis [4, 5] and intestinal perforation [6, 7]. Accordingly, an important goal in cancer therapy is to develop novel and safer tumor anti-angiogenic agents, which in turn depends on a thorough understanding of the biology of TECs.

TUMOR BLOOD VESSELS ARE MORPHOLOGICALLY ABNORMAL

Tumor blood vessels differ in many ways from normal blood vessels (Fig. 1a). Specifically, tumor vessels are not organized in the same hierarchical branching pattern (*i.e.*, from arteries to capillaries and then veins) as the normal vasculature [8]. Their underlying basement membranes are of varying thicknesses, and their TECs do not form regular monolayers [9], unlike in normal blood vessels [10]. Although pericytes are present, they form abnormally loose association with TECs [11]. Consequently, tumor blood vessels are leaky. Other abnormalities of tumor blood vessels have been attributed to the unbalanced expression of angiogenic factors and inhibitors (Fig. 1b). In addition to the above

characteristics, tumor blood vessels are often immature morphologically, The high interstitial fluid pressure in cancer causes vessel collapse and blood flow is compromised. Furthermore, tumor vessels show chaotic blood flow and they are leaky because of the loose interconnections in endothelium [12]. These features of tumor vasculature may be one of reason why cancers are usually hypoxia even though they are highly vascularized. Hypoxia in cancer is the cause of resistance to radiation therapy [13].




Fig. (1). Differences in the blood vessels of tumors and normal tissue.

(a) Tumor vessels show excessive branching but lack the arteriole-capillary-venule hierarchy. As a result, blood flow through these vessels is chaotic. Resident pericytes in tumors associate with endothelial cells loosely. **(b)** Tumors are characterized by imbalances between the levels of pro-angiogenic (activators) and anti-angiogenic (inhibitors) factors. The up-regulation of activators vs. inhibitors causes an angiogenic switch in the tumors.

TECs are morphologically irregular, with long cytoplasmic projections extending across the lumen, whereas NEC are uniform. The endothelial gaps and transcellular fenestrae in the walls of tumor blood vessels result in hemorrhage and plasma leakage, two common properties of tumors. Moreover, they allow filling in by adjacent tumor cells and provide a mechanism for tumor cell

Metastatic Cancer Stem Cell Niche and the Toll-like Receptor 4 (TLR4)-mediated Premetastatic Microenvironment

Takeshi Tomita*, Atsuko Deguchi* and Yoshiro Maru

Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan

Abstract: Cancer metastasis is one of the most crucial problems in the field of medical research. There are two types of approaches to find a new way to treat cancer metastasis; Targeting cancer stem cells, or stromal cells in the premetastatic phase. Interactions between these two elements synergistically enhance the survival of metastatic cancer cells and promote their re-growth in the distant organ. In this review, first we summarize the recent trends in cancer stem cell studies. Then, we discuss the premetastatic phase, based on our investigations. We also review various types of tumor-associated stromal cells (monocyte/macrophage, fibroblast, adipocyte, dendritic cell, neutrophil, and natural killer cell) in relations with the tumor microenvironment formation. Moreover, dormant tumor cells and circulating tumor cells are included in this review.

Keywords: Biglycan, CCL2, CCR2, Circulating tumor cell, Dormant cell, EMT, Eph, Ephrin A1, HMGB1, Inflammation, MD-2, Metalloprotease, Organ tropism, Premetastatic microenvironment, S100A8, SAA3, TGF- β , TLR4, TNF α , VEGF.

I. OVERVIEW

I-a. Outline of Tumor Metastasis

It is often said that tumor metastasis do not just happen. Actually, it is a sequence

* **Corresponding authors Takeshi Tomita and Atsuko Deguchi:** Department of Pharmacology, Tokyo Women's Medical University, 8-1 Kawada, Shinjuku, Tokyo, 162-8666, Japan; Tel/Fax: +81-3-5269-7417; Emails: tomitat@research.twmu.ac.jp, deguchi@research.twmu.ac.jp

of events including dissemination of tumor cells from (a) primary tumor formation, (b) local invasion, (c) intravasation, (d) cell survival during circulation in blood vessels, (e) extravasation, (f) settlement of tumor cells at distant organ, and (g) metastatic tumor regrowth. Every single step has been intensively scrutinized so that myriads of reports are available. The outline of “the premetastatic phase”/metastasis is shown in Fig. (1).




Fig. (1). Outline of the pre-metastatic phase.

The recruitment of myeloid-derived cells is a crucial step in metastasis. In the early phase of the primary tumor, it is not ready for myeloid-derived cells (monocytes, MDSCs) to recruit primary tumor sites and distant organs (in this case, lung; Don't walk). Once tumors develop certain size, the primary tumor microenvironment secretes cytokines/chemokines (*i.e.* VEGF, TNF α , and TGF- β) to supply to myeloid-derived cells. These cytokines can send a signal to myeloid-derived cells in bone marrow as “Walk”.

Interestingly, different molecule comes forward with every single step toward metastasis. The data that knockdown of individual molecular, any given molecule

highlighted in the research, by using knockout mouse or shRNA techniques seriously did hurt macroscopic metastasis indicate that tumor metastasis is a balance as subtle as on the edge of a cliff. In other words, since many molecules should be orchestrated for cancer metastasis, just disordered one piece is enough to make it incomplete.

For instance, cathepsins were indispensable to local tumor invasion [1, 2]. These metalloproteases were generated by macrophages upon stimulation of IL-4, secreted by tumor cells or T cells nearby [1, 3]. During intravasation, key molecules between tumor cells and macrophages became epidermal growth factor (EGF) and colony stimulating factor-1 (CSF-1) instead [4]. Selectins prolonged the lifetime of tumor cells in the blood vessels [5]. Metadherin [6] and angiopoietin-like 4 (Angptl4 [7],) were necessary for tumor cells to extravasate in a distant organ. In order to commence the colonization, immigrated tumor cells required matrix metalloproteinase-9 (MMP-9) and stromal cell derived factor-1 (SDF-1) released from stromal cells [8]. Osteopontin from bone marrow derived cells were needed for further growth [9]. Vascular cell adhesion molecule-1 (VCAM-1) is one of the most hopeful therapeutic target molecules. VCAM-1 expressed on the metastatic tumor cells bound integrin $\alpha 4\beta 1$ on tumor-associated macrophages. With the ligand binding, the PI3K-Akt signaling pathway was activated, which caused dissemination of tumor cells in lungs [10, 11]. Again, these proteins are just a small portion. Different types of tumor cells may ask different kinds of molecular sets to metastasize, implying that custom-made regimens should be designed to prevent metastasis. Thus, this fact makes tumor treatment more painstaking.

Recent studies continue to shed light on potential therapeutic target molecules. Retinoic acid receptor responder protein 3 (RARRES3) was found out to be a metastasis suppressor. Phospholipase A1/A2 activity of this protein played an important role to keep tumor cells from initiating metastasis in the lungs [12]. Repression of thrombospondin-1, anti-angiogenic factor, was essential for tumor growth. Interestingly, an investigation uncovered that regulation of thrombospondin-1 in fibroblast was distinct from that in epithelial cells [13]. Cathepsin S promoted brain metastasis by cleaving junctional adhesion molecule-B (JAM-B) to facilitate tumor cells passing through the blood brain barrier [14]. A

Cancer Stem Cell and Clinical Cancer Metastasis in Surgical Oncology

Shoji Nakamori^{1,*} and Koji Morimoto^{1,2}

¹ Department of Hepato-Biliary-Pancreatic Surgery, Osaka National Hospital, Osaka, Japan

² Osaka Women's Junior College, Osaka, Japan

Abstract: The cancer stem cell (CSC) theory has emerged as an attractive hypothesis for tumor development and progression including metastasis. The theory suggests that tumors consist of subsets of cells with functional heterogeneity in which one small subset has the characteristics of stem cells. These stem cells have the capacity of both self-renewal and heterogeneous differentiation into cancer cells that comprise the tumor. They can also play an important role in invasion, metastasis and, finally, recurrence. Based on the pathogenesis of the cancer metastasis, the recurrences after curative surgery probably develop from the proliferation of occult micro-metastases already established at the time of surgery. The attractive ideas about CSCs hypothesis in metastasis can partially explain the concept of minimal residual disease like occult micro-metastases after curative resections. CSC hypothesis in clinical metastasis is now giving a deep impact on surgical oncology. Efforts to develop diagnostic and therapeutic approach with the successful results from CSC studies would lead to impressive improvement for cancer patients in surgery.

Keywords: Adjuvant chemotherapy, Biomarker, Cancer, Cancer stem cell (CSC), Circulating tumor cells (CTC), Disseminating tumor cells (DTC), Epithelial-mesenchymal transition (EMT), Mesenchymal-epithelial transition (MET), Metastasis, Micro-metastases, Prognosis, Recurrence, R0 resection, Surgery, Surgical oncology, Target therapy.

* Corresponding author **Shoji Nakamori:** Department of Hepatobiliary-Pancreatic Surgery, Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan; Tel: +81-6-6942-1331; Fax: +81-6-6943-6467; Email: nakamori@onh.go.jp.

Takanori Kawaguchi (Ed.)

All rights reserved-© 2016 Bentham Science Publishers

INTRODUCTION

Cancer metastasis consists of a multistage process during which cancer cells spread from the primary to distant organs [1]. At first, cancer cells detach from the extracellular matrix and invade the surrounding tissue. Cancer cells migrate toward a vascular blood supply by localized proteolysis at the tumor cell-basement membrane interface and then, penetrate thin-walled vessels to gain access to the systemic circulation (intravasation). Cancer cells circulate as individual cells or clusters with some blood components like platelets and arrest in the distant microvascular beds by passive or active mechanisms. Cancer cells migrate into arrested remote organ through the endothelial cells (extravasation) by multiple mechanisms. Adherent cancer cells may migrate across intracellular junctions between adjacent endothelial cells (paracellular route) or they may penetrate through the body of a single endothelial cell (transcellular route). After gaining access to the underlying tissue of arrested remote organ, cancer cells establish reciprocal signaling networks with surrounding stromal cells to promote their growth including neo-vascularization and finally establish metastatic focus. To survive through the multistage process, cancer cells should possess the ability to escape from physical pressures in the vascular stream, anoikis, apoptosis, and the host's immunologic defenses. Although the rate of cancer cell release in cancer patients is unknown, metastasis is regarded as a highly inefficient process in that less than 0.01% of circulating cancer cells eventually succeeds in forming secondary tumor growth by experimental model [2]. This is a result of the elimination of circulating tumor cells that fail to complete all steps in the metastatic process. The metastatic process is realized to be inefficient [3]. Therefore, it has been debatable whether a few cancer cells with fortunate survival and growth can develop the metastasis or whether a unique subpopulation of cancer cells with selective properties for growth and survival can develop the metastasis [4]. However, a lot of findings based on animal models and clinical studies suggest that human tumors are biologically heterogeneous [5] and that the process of clinical metastasis is selective [6].

Recently, the cancer stem cell (CSC) theory has emerged as an attractive hypothesis for tumor development and progression including metastasis [7, 8]. The theory suggests that tumors consist of subsets of cells with functional

heterogeneity in which one small subset has the characteristics of stem cells. These stem cells have the capacity of both self-renewal and heterogeneous differentiation into cancer cells that comprise the tumor [7]. They can also play an important role in invasion, metastasis and, finally, recurrence. Based on the recent findings, CSCs can induce cancer metastasis through multiple pathways and participate in angiogenesis directly and indirectly [9 - 11]. Furthermore, the migrating cancer stem cell concept [12] proposed that CSCs *in situ* can transform to migrating cancer stem cells by epithelial-mesenchymal transition (EMT). Then, they disseminate and form metastatic foci. Indeed, cells possessing both the stem and tumorigenic phenotypes of CSCs were derived from human mammary epithelial cells [13].

In this review, impact of CSCs in clinical metastasis is overviewed from surgical oncologist's aspects.

CLINICAL SIGNIFICANCE OF METASTASIS IN SURGERY

Despite the recent advances in diagnostic techniques for early detection of cancer and the progress in therapeutic procedures including surgical resection, chemotherapy, and radiation therapy, prognosis of the patients with cancers is still unsatisfactory. Major problems for the cancer treatment are not the primary tumors but the formation of metastases [14]. Recurrence is the most critical situation in the treatment of cancer patients after curative surgery. Almost all of cancer recurrences are due to metastasis on the distant organs or regional lymph nodes if surgical resection is undergone in curative intent. Clinically, patients with distant metastasis are hardly appropriate to surgical resection which possibly offers the patients with solid cancer an opportunity to live longer and cure. Even though patients underwent curative resection (surgical macroscopically zero residual: R0) resections at the surgery, a significant number of the patients have recurrence with developing systemic metastasis at distant organ within a few years after surgery. Main reason of cancer death remains to be recurrence due to the metastasis. Based on the pathogenesis of the cancer metastasis, these recurrences probably develop from the proliferation of occult micro-metastases already established at the time of surgery [15, 16]. Clinical metastasis, however, detected after surgery varies from patient to patient. Multiple liver metastases

SUBJECT INDEX**A**

Acute myeloid leukemia (AML) 6, 114
 Adherent cancer cells 110
 Adjuvant chemotherapy 109, 117, 118, 119
 A-Dystroglycan glycosylation 39
 Aerobic glycolysis 9
 Aldehyde dehydrogenase 12, 116
 Altered glycan expression 34
 Aneuploidy 64
 Angiogenesis 61, 62, 65, 111, 120
 Angiogenic dormancy 94
 Angiogenic factor 61, 62
 Anti-angiogenic therapies 61, 62, 68
 Anti-glycan antibodies 26
 Anti-tumor activities 92

B

B-blood type glycan expressions 29
 Biglycan 74, 87, 88, 89
 Biglycan protein 87
 Biglycan-TLR4/MD-2 interactions 87
 Biomarker expression 8, 116
 Biomarkers for detection of cancer stem cells 114
 Biosynthetic pathway for type-1-chain lactosamine glycans 47
 Bladder cancer ALDH1 117
 Bladder cancer EMA-/CD44v6 114
 Blood vessels 61, 62, 63, 65, 67, 75, 76, 79, 96, 98, 99
 endothelial cells lining tumor 61
 formed tumor 61
 line tumor 62

Bone marrow 12, 15, 37, 67, 68, 75, 76, 80, 85, 95, 115
 Bone metastasis 77, 89, 92
 abrogate 77
 Brain metastasis 76, 77
 promoted 76
 Breast cancer 11, 45, 48, 78, 94, 114, 117, 119
 human 11
 spontaneous luminal 94
 Breast cancer cells 13, 15, 82, 83, 92
 Breast cancer lapatinib 119
 Breast cancer metastasis 90
 Breast cancer stem cells 39, 85
 Breast cancer trastuzumab 120
 Breast cancer tumor 39
 Bronchiolar bud cells 36, 37

C

CAIX inhibition 90
 Cancer-associated glycans 24, 26, 27, 28, 29, 30, 31, 32, 33, 35, 40, 47, 48
 classical 47
 induction of 30, 40
 sialyl Lewis X 28
 sialyl Lewis A 40
 Cancer-associated silencing 33
 Cancer cell clones 34
 Cancer cell growth 14
 Cancer cell nests 34
 Cancer cell proliferation 29
 Cancer cell release 110
 Cancer cell resemble 4

- Cancer cells 4, 8, 10, 25, 26, 31, 34, 35, 38, 40, 41, 42, 90, 91, 110, 114, 115, 118
 - differentiated 8, 90, 114
- Cancer cells detach 110
- Cancer cell survival 91
- Cancer death 111
- Cancer diseases 94
- Cancer invasion 115
- Cancer lesions 115
- Cancer microenvironment 42
- Cancer patients, esophageal 90
- Cancer progression 28, 95
 - preventing 28
 - restart 95
- Cancer recurrences 111
- Cancer-related deaths 3
- Cancers 3, 4, 5, 12, 16, 24, 25, 26, 27, 28, 29, 30, 33, 34, 35, 42, 47, 48, 63, 83, 92, 98, 99, 111, 112, 114, 119
 - advanced-stage 34
 - extracervical 99
 - inoperable 119
 - liver 114
 - metastatic 3, 16
 - pancreas 47
 - pancreas head 112
 - pancreatic 12, 112
 - papillary thyroid 30
 - positive 92
 - prostate 27, 83
 - solid 111
 - unknown primary 98
- Cancer stem cell and markers 81
- Cancer stem cell glycans 49
- Cancer stem cell markers 13, 24, 46, 48, 49
- Cancer stem cell models 84
- Cancer stem cell niche 4, 86, 90, 92
- Cancer stem cell phenotype 5
- Cancer stem cell pools, multiple 81
- Cancer stem cells and EMT 82
- Cancer stem cell self-renewal 84
- Cancer stem cell theory 25, 120
- Cancer stem-like cell 25
- Cancer survivors 94
- Cancer therapy 33, 61, 62, 68
- Cancer tissues 40
- Cancer treatment 62, 111, 118
- Carcinogenesis 4, 25, 26, 28, 30, 31, 33
 - early stages of 26, 31
- Carcinoid tumors 10
- Carcinoma 9, 11, 12, 65, 85, 98, 99
 - metastatic 98, 99
- Carcinoma cells 85
 - mammary 12
- Cathepsin 76, 77
- Cell markers 37, 81
 - glycan stem 37
 - universal cancer stem 81
- Cell proliferation status 28
- Cells 4, 6, 7, 8, 9, 10, 11, 13, 14, 16, 25, 27, 31, 35, 39, 42, 45, 47, 64, 68, 75, 79, 80, 81, 83, 85, 92, 93, 94, 97, 98, 113, 118,
 - antigen-presenting 93
 - cultured 93
 - glioblastoma 68
 - hilum 85
 - human 64
 - inflammatory 42
 - initiating 8, 25, 39

- lymphoma 68
- melanoma 9
- microdissected 27
- myeloid-derived 75
- neoplastic 8, 85
- non-CSCs 118
- non-malignant 35
- non-tumorigenic 113
- premature 93
- quiescent 10, 80
- resistant 80
- single 6, 81, 97
- sustaining 16
- tumor-associated 79, 98
- tumorigenic 4
- tumor-propagating 25
- Cells colonize 15
- Cell surface glycan expression 39, 40
- Cell surface glycans 24, 31, 42, 48
- Cell survival, mediated cancer 91
- Chain lactosamine 47, 48
- Chain lactosamine glycans 46, 47, 48
- Chemoresistance 80, 81, 118
- Chemoresistant tumors 92
- Chemotherapeutic agents 64, 68, 118, 120
- ChIP assays in human colon cancer HT29 cells 30
- Circulating cancer cells 110
- Circulating tumor cell detection system 97
- Circulating tumor cells 74, 77, 78, 79, 86, 96, 97, 98, 109, 110, 115
 - targeting 77
- Circulating tumor cells (CTCs) 74, 77, 78, 79, 86, 96, 97, 98, 109, 110, 115
- Circulating tumor DNA 96
- Classical cancer stem cell model 84
- Clinical metastasis 109, 110, 111, 112, 115
- Clonogenicity 3, 4
- Clustered tumor cells 97
- C-Myc 35, 37, 43
- Colon cancer cells 30, 31, 41
- Colon cancers 12, 13, 29
- Colon cancer tissues 26
- Colon carcinogenesis 27
- Colonic cancer cells 27
- Colonies, metastatic 10, 13, 14
- Colorectal cancer CD133+ 114, 117
- Colorectal cancer Cetuximab 120
- Complex abnormal karyotypes 66
- Computational simulation 87, 88
- Computed tomography 112
- Conditions, hypoxic 35, 37, 90
- Contamination of human tumor cells 64
- Critical components of metastasis 10
- CSC and metastatic cells markers 7
- CSC hypothesis in clinical metastasis 109
- CSC niches 14, 118, 120
- CSCs 3, 6, 8, 9
 - solid tumor 8, 9
 - tumor-initiating 3
 - tumor-sustaining 6
- CSCs and metastatic cancer cells 4, 16
- CSCs and metastatic cells 9, 13, 15, 16
- CSCs hypothesis in metastasis 109, 112
- CSCs in clinical metastasis 111

- CSCs in human tumor specimen 116
CSCs in solid tumors 119
CTCs 96, 97
 classical 96, 97
 proliferative 96
Cultured colon cancer cells 47
Cultures, monolayer 77
Curative surgery 109, 111
Cycling cells, fastest 7
Cytogenetic abnormalities 64, 66, 68
Cytokines 68, 75, 84, 85, 91, 98
- D**
- Decorin 87, 97
Dendritic cells 74, 93, 94, 95
 tumor-associated 93, 94
Desmoid tumors 10
Destructed proliferating tumor cells 80
Diphtheria toxin (DT) 64
Disialyl Lewis A 26, 27, 28
Disialyl Lewis A glycan 27
Disseminated cancer cells 11, 13, 14
Disseminated tumor cells 15, 81, 95
 observing 95
Disseminating tumor cells (DTCs) 109, 115
DNA fragments 96
DNA methylation 25, 29, 83
Dormant, dormant cells 95
Dormant state 95
Dormant tumor 94
Dormant tumor cells 74, 94, 95
 eradicating 95
- Drugs 33, 62, 66
 anti-angiogenic 62
 anti-cancer 66
 epigenetic 33
- E**
- Ectopic tumors 83
Efficacy, metastatic 10, 11, 13
Embryology 48
Embryonic development 32, 41, 42
Embryonic stem (ES) cells 25, 42
Embryonic stem cell markers 24, 48
Embryonic stem cells 24, 32, 33, 35, 37, 42, 45, 48, 49
EMT-induced cancer 38
EMT-induced cancer cells 40
EMT of cultured colon cancer cells 47
Endogenous ligands 86, 87, 88, 89, 99
Endoplasmic 89
Endothelial cells 8, 14, 34, 36, 37, 38, 61, 62, 63, 64, 65, 68, 110
 adjacent 110
 immature 36
 normal 62, 64, 65
Endothelial progenitor cells, derived 68
Enumerating tumor cells 96
Ephrin A1 74
Epidermal growth factor (EGF) 38, 64, 76

- Epigenetic changes 33, 83, 91
- Epigenetic regulations 13, 15, 83
- Epigenetic silencing 25, 26, 27, 28, 29, 30, 31, 33, 34
 - cancer-associated 29, 33
 - developmental 33
 - mechanisms for 29, 31
- Epithelial cells 11, 26, 27, 31, 32, 36, 38, 76, 79, 82, 111
 - fully-differentiated 32
 - mature 31
 - non-malignant 26, 27
 - normal 26, 82
- Epithelial-mesenchymal transition 4, 24, 25, 38, 49, 82
- Epithelial-mesenchymal transition (EMT) 7, 11, 12, 13, 24, 25, 38, 39, 40, 41, 42, 82, 83, 84, 115
- Epithelialmesencymal transition 109
- E-selectins on endothelial cells 34
- Extravasate 10, 12, 76
- Extravasation 75, 77, 110
- F**
- Fibroblasts 8, 64, 74, 76, 85, 92, 93
 - tumor-associated 92, 93
- Filopodium-like protrusions (FLP) 77
- FLP formation 77
- G**
- Gastric cancer 114
- Gastric cancer CD133+ 117
- Gastric cancer Trastzumab 120
- Gb5, sialylated 43, 44
- GBM cells 14
- Gene expression 3, 4, 13, 15, 25, 30, 65
- Gene expression patterns 11, 81, 82, 92, 97
- Genes 9, 12, 13, 27, 28, 29, 30, 31, 32, 33, 34, 38, 39, 40, 82
 - homeobox 13
 - transcription of 33, 34
- Genomic integrity 7
- Globoseries glycolipids 44, 45, 46, 48
- Glycan alteration 38
- Glycan epitopes 29, 43
 - cancer-associated 29
- Glycan expression 24, 28, 29, 30, 31, 34, 46, 49
 - cell-associated 46
- Glycan markers 24, 45, 46, 48
- Glycan-related genes 24, 26, 29, 30, 38, 40, 41, 49
 - normal 30
- Glycan-related genes during 28
- Glycans 24, 25, 26, 27, 30, 31, 34, 35, 38, 41, 42, 44, 45, 46, 47, 48, 49
 - abnormal 30
 - cell-associated 44, 46
 - classical 45
 - colon cancer 27
 - embryonic stem cell 49
 - globoseries 48
 - tumor marker 24, 48
- Glycan structures 43, 45
- Glycan sulfation 28

Glycan synthesis 27, 29, 34, 40
Glycolipids 34, 39, 43, 44, 45, 46
Glycoproteins 43, 46
Gram-positive bacteria 89
Growing tumor cells 67
Growth signals 15

H

Hanganatziu-Deicher antigen 35
HDAC inhibitors 29, 30
Hematopoietic cells and immune cells 12
Hematopoietic progenitor cells 10
Hematopoietic stem cells (HSCs) 10, 15, 37
Heterogeneity 4, 15, 61, 65, 111
HIF-1 α 12, 34, 35
Highly metastatic (HM) 65, 66, 113
Hippel-Lindau tumor suppressor 90
Histone deacetylation 25, 29
Histone methylation 25
HSCs and leukemic cells 10
Human cancer cells 45
Human cancers 24, 29, 45, 48, 114
Human cardiac myosin 89
Human colon cancer cells DLD-1 40
Human colon cancer HT29 cells 30
Human EC cells 43
Human embryonic and cancer stem cell markers 46
Human embryonic stem cells 24, 35, 42, 45, 46, 48
Human teratocarcinoma cells 48
Human tumor cells 64
Human tumor specimen 116
Hyaluronan 38, 39, 89

Hypoxia 12, 24, 25, 34, 35, 37, 38, 61, 63, 67, 68, 84, 85, 90, 94
Hypoxia-inducible factors (HIFs) 25, 34, 36, 37
Hypoxia-resistant cancer cells 34
Hypoxia tolerant 95, 96
Hypoxic environments 34, 38

I

IL-6, activated 91, 92
IL-8 productions in cancer stem cells 92
Immigrated tumor cells 76
Immune cells 8, 12, 28, 77, 94, 95, 97
tumor-associated 94
Immune surveillance 94, 95
Implanted tumor cells emit cytokine signals 79
Inflammatory reactions 79, 98
Injected tumor cell 77
Integrin-linked kinase (ILK) 77
Invasion 3, 61, 76, 82, 86, 87, 93, 109, 111
accelerated tumor cell 87
local tumor 76
Invasion front 40
IPS cells 37, 42, 46
human 42, 46
Isolated circulating tumor cells 97

L

Lactoseries glycans recently emerging 46
Leukemia, acute myeloid 6, 114

- Leukemia cells 10
- Liver cancer EpCAM 117
- Liver cancer stem cells 83
- LM-TECs 65, 66
- LM tumors 65
- Low metastatic (LM) 65, 66
- Luminal cells, differentiated 82
- Luminal progenitor cells 82
- Lung cancer CD133+ 116
- Lymph node metastasis 89, 90
 - proximal 90
- Lymph nodes 89, 90
 - metastasis-free 90
 - sentinel 89, 90
- Lysosomes 35
- M**
- Macro-metastasis 77
- Macrophage colony stimulating factor (MCSF) 92
- Macrophages 76, 87, 92, 95, 97
 - tumor-associated 76, 92, 97
- Macroscopic tumor nodules 90
- Malignant cancer cells 8
- Malignant cells 5
- Malignant transformation 24, 26, 27, 28, 32, 48
- Malignant tumor 80, 83
- Mammary epithelium 11
- Mammary tumor cells switch, triggered 95
- Mammary tumors 9
- Mammary tumor virus-polyoma middle 94
- Mechanisms of metastasis 12
- Mesenchymal-epithelial transition 109, 115
- Metalloproteases 74, 76
- Metastasis 10, 11, 13, 34, 41, 76, 78, 87, 89, 90, 111, 112, 115, 119
 - avert 10
 - breast cancer cell 78
 - colon cancer cell 13
 - developing systemic 111
 - distant 111, 112
 - distant organ 89
 - hematogenous 34, 41
 - increased 13
 - initiating 76
 - lung 86, 87, 90
 - lymph-node 115
 - macroscopic 11, 76
 - multiple 119
 - overt 89
- Metastasis-initiating cells 4, 10
- Metastasis pattern 78
- Metastasis procedures 82
- Metastasis rate 97, 117
- Metastasis suppressor 76
- Metastatic breast tumors 12
- Metastatic cancer cell biology 3
- Metastatic cancer cells 4, 10, 12, 15, 16, 74
- Metastatic cell 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16
 - growth of 15
- Metastatic cells markers 7
- Metastatic colonization 4, 7, 11, 13
- Metastatic foci 42, 110, 111
- Metastatic initiating cells 16
- Metastatic niche 4, 14, 15

- Metastatic sites 11, 77, 79, 82, 95, 117, 118
Metastatic tumor cells 12, 76
Metastatic tumor regrowth phase 83
Metastatic tumors 66, 82, 83, 115
 low 66
Migrating tumor cells 86
Migratory stem cells 15
Monosodium urate crystals 89
Multiple liver metastases 111, 112
Murine brain tumors 45
Mutations, accumulating tumorigenic 32
Mycobacteria 89
Mycoplasma 89
- N**
- Natural killer cells 74, 94
Neck cancer Bmi-1 116
Neck cancer CD44 114
Negative breast tumor 92
NeuGc-containing glycans 35
Neural crest 11, 15
Neural stem/progenitor cells, normal 81
Neural tube 11
NF- κ B 98
NF- κ B oscillation 98
N-glycans 39
 branched 39
Non-cancer stem cells 84, 90, 99, 113
Non-small cell lung cancer Sca 114
Normal endothelial cells (NECs) 62, 63, 64, 65, 66, 67, 68
Normal glycan expression 33
Normal glycan sialyl 6-sulfo Lewis X 28
Normal sialyl 6-sulfo Lewis X glycan 31
Normal stem cells 4, 5, 7, 8, 11, 13, 14, 15, 16, 25, 32, 35, 41, 42, 80
Normal tissue stem cells 25, 31
Notch signaling 14
Nutrition, cells supply 93
- O**
- Occult micro-metastases 109, 111, 112, 118
O-glycans 31, 39
Organogenesis 25, 37
Organ tropism 74, 78, 79
Organ tropism of tumor metastasis 78
Otherwise-indolent tumor 80
Ovarian cancer CD44 114
Ovarian cancer CD133+ 117
Ovarian cancer cells 9, 35
 cultured 35
Ovarian cancer trastuzumab 120
- P**
- Pancreatic cancer ALDH1 117
Pancreatic cancer CD44 114
Pancreatic cancer cell line AsPC-1 95
Pancreatic cancer erlotinib 119
Parenchymal cells 31, 33
 mature 33
Peptidoglycan 89
Pericytes 62, 65, 68

- Phenotypes 3, 4, 5, 7, 44, 64, 65, 67, 92, 98, 115, 119
 cancer stem cell marker 115
 pro-angiogenic 64, 65, 67
Plastic cancer stem cell model 84
Plasticity 13, 41, 42, 84
 conferring tumor cells genomic 84
Pluripotency 4, 35
Positive myeloid cells, double 91
Preadipocytes 93
Preferential expression 26, 31
Premetastatic microenvironment 74
Pre-metastatic niche 79, 85, 86, 88, 98, 99
Pre-metastatic phase 75, 79, 85, 86, 90, 98
Primary prostate cancer 88
Primary site tumors 99
Primary tumor 10, 11, 15, 75, 77, 79, 85, 96, 97, 99, 111, 112, 113, 115
 aggressive 10
Primary tumor-derived factors 85
Primary tumor locations 99
Primary tumor sites 62, 75, 81, 83, 92, 97
Process 110
 metastatic 110
 multistage 110
Prognosis 90, 92, 95, 96, 109, 111, 115, 116
 poor 90, 92, 95, 96, 116
Proliferating cancer cells 14
Proliferating cells 5, 8
Proliferating tumor 10
Proliferating tumor cells, abolished 80
Proliferation 6, 8, 14, 28, 82, 91, 95, 109, 111
 cell 28
Prostate cancer CD44 114, 117
Prostate cancer cells 78
Prostate tumor cells 95
Protein data bank (PDB) 88
Proteins 28, 76, 77, 87, 88, 89, 94
 surfactant 87
 tumor-derived 89, 94
Pro-tumor 83, 93, 94
 N2 94
 substance 93
- Q**
- Quiescence 4, 5, 7, 8
Quiescent cancer cells 4
- R**
- Recurrent tumor 4
Reinitiate tumors 8
Renal cancer cells 91
Renal cancer temisirolimus 119
Resected breast cancer tumors 116, 119
- S**
- Safer tumor anti-angiogenic agents 62
Salvage pathway 35
Sda blood group substance in colon cancers 29
Sentinel circulating tumor cells 96
Sequence, normal-adenoma-carcinoma 27
Shorter-lived transit-amplifying cells 5
Sialic acids 35, 46

- Sialyl 6-sulfo Lewis X 26, 27, 28, 31, 32
- Sialyl Lewis A 24, 25, 26, 27, 29, 31, 34, 38, 40, 41, 46, 47, 48
- Sialyl Lewis A glycans 47
- Sialyl Lewis X 24, 25, 27, 29, 31, 32, 34, 36, 37, 38, 39, 40, 41, 48
- Sialyl Lewis X glycans 26, 36, 41
- Signaling pathways 118, 120
- Single strand RNA 89
- SiRNA 89
- Skin cancer vismodegib 119
- SLC26A2 gene 28, 30, 31
- Solid tumors 8, 9, 16, 68, 80, 96, 119
- Solitary dormant tumor cell 95
- Solitary tumor 80
- Squamous cell carcinoma cancer cells 7
- SSEA-1 glycan 37, 45
- SSEA-3, pluripotency marker glycan 35
- SSEA-3 and SSEA-4 glycans 42, 45
- SSEA-4 glycans 42, 45
- SSEA-5 glycans 46
- Stem-cell 9, 24, 37, 49
- Stem cell marker 12, 97
- Stem cell niche 4, 13, 14, 15, 85
normal 13, 15
- Stem cell phenotypes 3, 11, 115
- Stem cells 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 24, 25, 31, 32, 33, 37, 38, 39, 45, 46, 48, 80, 81, 82, 84, 86, 90, 91, 92, 93, 99, 109, 111, 119
behavior of cancer 25, 84
cardiac 37
characteristics of 109, 111
colon cancer 32, 39
conversion of non-cancer 84, 99
definition of cancer 80
generated mammary 82
hematopoietic 7, 10, 37
human neural 45
intestinal 31, 33
mammary 9
mesenchymal 37, 91, 92, 93
metastatic 81
migrating cancer 111
mouse pluripotent cancer 90
native 84
normal intestinal 32
normal resident 16
quiescent 5
renowned 86
resident 6
resistant cancer 119
specialized lineage-committed 37
stimulated cancer 92
surrounding normal 14
tissue 33
- Stromal cells 67, 68, 74, 76, 78, 79, 85, 91, 97, 110
associated 67
surrounding 78, 110
tumor-associated 74, 81, 92
- Sulfate transporter 25, 27, 28, 29, 31, 32
- Suppressive effects 28
- Suppressor cells, derived 87
- Sustain migrating cells 11
- Synthetic pathway 30, 34, 35, 44, 46, 47

T

- Targeting cancer stem cells 74
- Target occult micro-metastases 118
- Target therapy 109, 119, 120
- TEC HETEROGENEITY 65, 67, 68
- TECs, isolated 64
- Temozolomide treatment 80
- Teratoma cells 5
- Terminal bud cells 36, 37
- TGF β 38, 39
- Therapy 14, 15, 33, 62, 118, 119, 120
 - adjuvant 119, 120
 - anticancer 14
 - anti-cancer 15
- Therapy-resistant cancer cells 5
- Thrombospondin-1 76
- Time stromal cells accommodating 86
- Tissues 5, 7, 8, 9, 11, 13, 15, 25, 30, 31, 32, 37, 45, 110, 116, 119
 - embryonic 5
 - resected breast cancer 116
- TLR, exogenous and endogenous ligands for 88, 89
- TNF α 74, 75, 85, 91
- Tracheal bud cells 36
- Transcription factors 34, 37, 45, 49, 82, 83, 84
- Transition, epithelial-to-mesenchymal 11
- Trimethylation, histone 29, 30, 31, 32
- Tumor angiogenesis 61, 62, 64
- Tumor antigens 94
- Tumor-associated adipocytes 93
- Tumor-associated
 - Monocytes/macrophages 92
- Tumor-associated natural killer cells 94
- Tumor-associated neutrophils 94
- Tumor blood vessels 61, 62, 63, 65, 67
- Tumor blood vessels result 63
- Tumor blood vessels supply 62
- Tumor cell clusters 97
- Tumor cell contaminants 64
- Tumor cell dissemination 85
- Tumor cell extravasation 98
- Tumor cell homing assay 98
- Tumor cell number 96
- Tumor cells 62, 63, 67, 75, 76, 77, 78, 79, 81, 82, 91, 92, 93, 94, 95, 97
 - adjacent 63
 - migrated 78
 - single 97
 - stimulated 91
 - targeting 62
- Tumor cells in cellular dormancy switch 94
- Tumor cells metastasize 61
- Tumor cells passing 76
- Tumor cells proliferate 92
- Tumor cells propensity 78
- Tumor cell subpopulation 113
- Tumor cell subpopulations, minor 83
- Tumor cell traffics 77, 78
- Tumor cell-tumor cell communications 98
- Tumor destruction 16
- Tumor development 109, 110
- Tumor development and metastasis 113
- Tumor dormancy 94

- Tumor endothelial cells 64
Tumor formation 75, 83, 91, 120
 primary 75, 83
Tumor growth 8, 76, 83, 87, 90, 92, 93, 94, 110
 accelerated 92
 drive 8
 secondary 110
Tumor growth and metastasis 61
Tumor heterogeneity 5, 83
Tumor hypoxia 34
Tumorigenesis 4, 8, 9, 13, 90, 96
Tumorigenic cancer cells 5, 16
Tumorigenic capacity 7, 9
 increased 9
Tumorigenicity 83
Tumorigenic phenotypes 111
Tumor infiltrating 94
Tumor-initiating ability 96
Tumor initiating cell 4, 5, 25
Tumor malignancy 67, 83
Tumor mass 80
Tumor metastasis 66, 74, 76, 77, 78, 79, 91, 92
 brain 91
Tumor metastasis liken 78
Tumor microenvironment 61, 68, 86, 90, 95
Tumor microenvironmental factors 61
Tumor microenvironment formation 74
Tumor neovascularization 66
Tumor progression 4, 5, 7, 8, 62, 67, 84, 94, 95, 96, 116
Tumor proliferation 92, 93
 rapid 93
Tumor recurrence 116
Tumor regrowth, metastatic 75
Tumor revascularization 68
Tumors 5, 7, 8, 15, 16, 61, 62, 63, 64, 66, 67, 68, 80, 81, 93, 95, 109, 110, 117
 growing 93
 human 64, 68, 110
 negative 117
Tumors colonize 3
Tumor-secreted factors 67
Tumor suppression factors 95
Tumor-suppressor loss 8
Tumor tissues 62, 64
Tumor treatment 76
Tumor type 15, 62, 65, 97, 114, 116, 117
Tumor vascularization 34
Tumor vasculature 63, 65
Tumor vasculogenesis 41
Tumor vessels 62, 63
- V**
- Vascular endothelial growth factor (VEGF) 37, 61, 64, 65, 66, 68, 74, 75, 85
Vascular E-selectin 34, 40, 41
Vascular progenitor cells 67
VEGF, tumor-derived 65
VHL and tumor metastasis 91
VHL in renal cancer cells 91
- Z**
- Zymosan 89